Registry to track the natural history of ATTR-CM
Real-World Characteristics and Treatment Patterns of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Multi-Country, Non-Interventional, Disease Registry
This study is tracking the experiences and treatments of adults with transthyretin amyloid cardiopathy (ATTR-CM) to better understand how the disease progresses and affects patients over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Taipei City) |
| Trial ID | NCT06651073 on ClinicalTrials.gov |
What this trial studies
This multi-center, non-interventional disease registry aims to characterize the natural history and treatment patterns of patients diagnosed with transthyretin amyloid cardiopathy (ATTR-CM). Data will be collected from routine clinical practice, focusing on demographic and clinical characteristics, treatment regimens, and patient outcomes. The study will include adult patients diagnosed with ATTR-CM after June 1, 2019, and will observe them until death, withdrawal, loss to follow-up, or the end of data collection, which is planned for 12 months after enrollment concludes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of ATTR-CM after June 1, 2019.
Not a fit: Patients without a confirmed diagnosis of ATTR-CM or those diagnosed before June 1, 2019, may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of ATTR-CM and improve patient management strategies.
How similar studies have performed: While this approach is observational and descriptive, similar registries have successfully provided valuable insights into other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Waivers of informed consent for deceased patients will be pursued if permitted by local regulation 2. Patients aged ≥18 years at first ATTR-CM diagnosis 3. Patients with confirmed diagnosis of ATTR-CM after 01 June 2019 Exclusion Criteria: * None
Where this trial is running
Taipei City
- National Taiwan University — Taipei City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.